Entera Bio Ltd.
Entera Bio Ltd. is listed today as Entera Bio Ltd.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2026 | $275 M | Private placement after listing | $250 million to $1 billion | equity, options | SEC | |
| Dec 2023 | $7 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Dec 2019 | $14 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Oct 2017 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Entera Bio Ltd. chose not to state its revenue in its newest notice of a funding round (Aug 2026).
SEC Form D · Aug 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2026
That is all the official record says: Entera Bio Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Entera Bio Ltd. are on record.
Investors#
No investor of Entera Bio Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 30 investors.
Largest shareholders today
Institutions holding Entera Bio Ltd. shares, as of Sep 30, 2026.
- BVF Inc/il$50 M9.79%
- Vivo Capital, LLC$36 M7.04%
- TCG Crossover Management, LLC$36 M7.04%
- Spruce Street Capital LP$33 M6.44%
- Commodore Capital LP$21 M4.22%
- Seven Fleet Capital Management LP$20 M3.94%
- Siren, L.L.C.$17 M3.45%
- Knoll Capital Management, LLC$17 M3.35%
- Driehaus Capital Management LLC$15 M2.97%
- Venrock Adviser, LLC$15 M2.93%
- Ra Capital Management, L.P.$14 M2.81%
- Logos Global Management LP$13 M2.53%
- Catalio Capital Management, LP$11 M2.25%
- Perceptive Advisors LLC$10 M1.97%
- Nantahala Capital Management, LLC$9 M1.73%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dana Yaacov-Garbeli | Chief Financial Officer | Aug 2026 |
| Miranda Toledano | Chief Executive Officer | Aug 2026 |
| Arthur Santora | Chief Medical Officer | Jan 2024 |
| Hillel Galitzer | Chief Operating Officer | Jan 2024 |
| Adam Gridley | Executive officer | Dec 2019 |
| Dana Yaacov | Executive officer | Dec 2019 |
| Phillip Schwartz | Executive officer | Dec 2019 |
| Roger Garceau | Executive officer | Dec 2019 |
| Geno J. Germano | Chairman of the Board | Aug 2026 |
| Haya Taitel | Director | Aug 2026 |
| Miranda Toledano | Chief Executive Officer | Aug 2026 |
| Sean J. Ellis | Director | Aug 2026 |
| Steven D. Rubin | Director | Aug 2026 |
| Yonatan Malca | Director | Aug 2026 |
| Gerald Lieberman | Chairman of the Board of Directors | Jan 2024 |
| Gerald M. Ostrov | Director | Jan 2024 |
| Roger Garceau | Director | Jan 2024 |
| Ron Mayron | Director | Jan 2024 |
| Sean Ellis | Director | Jan 2024 |
| Adam Gridley | Director | Dec 2019 |
| Faith Charles | Director | Dec 2019 |
| Gerald Ostrov | Director | Dec 2019 |
| Phillip Schwartz | Director | Dec 2019 |
| Zeev Bronfeld | Director | Dec 2019 |
| Chaim M. Davis | Director | Oct 2017 |
| David M. Ben Ami | Director | Oct 2017 |
| Luke M. Beshar | Director | Oct 2017 |
| Roger M. Garceau | Director | Oct 2017 |
| Yonatan M. Malca | Director | Oct 2017 |
| Zeev M. Bronfeld | Director | Oct 2017 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.